A carregar...
Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists
Currently, six glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are approved for treating type 2 diabetes. These fall into two classes based on their receptor activation: short‐acting exenatide twice daily and lixisenatide once daily; and longer‐acting liraglutide once daily, exenatide once week...
Na minha lista:
| Publicado no: | Diabetes Obes Metab |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Blackwell Publishing Ltd
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5064617/ https://ncbi.nlm.nih.gov/pubmed/26511102 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12596 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|